Drug researcher - Morphosys: over 100 million euros with capital increase
Drug researcher Morphosys has raised fresh money through a capital increase. A total of 3.4 million shares were placed with major investors at a price of 30 euros each, the SDax company announced on Thursday morning in Planegg near Munich. The Group put the gross proceeds at around 102.7 million euros. The Group intends to use the money to accelerate the market launch of its cancer drug Pelabresib and research into other drugs, among other things.
Morphosys had already announced the capital measure the previous evening and stated that it would have a liquidity requirement of around 250 million euros in 2024, including additional planned cost-cutting measures.
The placement price corresponds to a discount of 2.8 percent on the volume-weighted five-day average share price on the Xetra trading platform. Shareholders' subscription rights were excluded from the issue. The new shares are fully entitled to dividends for the current year and are expected to be traded from around December 19.
Read also:
- A clan member is punished here
- Traffic lawyer warns: Don't talk to the police!
- Will he be convicted as Jutta's murderer after 37 years?
- He also wanted to kill his cousin
Morphosys, a drug researcher based in Planegg near Munich, Bavaria, Germany, raised approximately 102.7 million euros through a capital increase to fund the market launch of its cancer drug Pelabresib and further research in the pharma sector. This move comes as the SDAX company aims to meet a liquidity requirement of around 250 million euros in 2024. Despite excluding shareholders' subscription rights, the new shares issued will be entitled to dividends for the current year.
Source: www.stern.de
